Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)

Cardona, Andrés F.; Ruíz-Patiño, Alejandro; Recondo, Gonzálo; Martin, C; Raez, Luis E.; Samtani, Suraj; Minata, José Nicolas; Blaquier, Juan Bautista; Enrico, Diego; Burotto, Mauricio; Ordóñez-Reyes, Camila; Chamorro, Diego F.; García-Robledo, Juan Esteban; Corrales, Luis; Zatarain-Barrón, Zyanya Lucía; Más, Luís; Sotelo, Carolina; Ricaurte, Luisa; Santoyo, Nicolás; Cuello, Mauricio; Mejía, Sergio; Jaller, Elvira; Vargas, Carlos; Carranza, Hernán; Otero, Jorge; Rodríguez, July; Archila, Pilar; Bermúdez, Maritza; Gámez, Tatiana; Lima, Vladmir Cláudio Cordeiro de; Freitas, Helano C.; Russo, Alessandro; Polo, Carolina; Malapelle, Umberto; Pérez, Diego; Rolfo, Christian; Viola, Lucia; Rosell, Rafael; Arrieta, Óscar

doi:10.1016/j.cllc.2022.06.001

Search citation statements

Order By: Relevance

Paper Sections

Select...

Selection and Order Of Use Of Egfr-tkis1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The T790M mutation is the predominant mechanism of acquired resistance to afatinib in primary tumors, with osimertinib demonstrating significant efficacy against this mutation [ 78 , 83 ]. In primary malignancies, the T790M mutation is the most common route of acquired resistance to afatinib; osimertinib has shown notable effectiveness against this mutation [119] , [120] , [121] . However, previous studies [122] indicate that the EGFR L718Q mutation, with or without the T790M mutation, accounts for about 10% of all patients exhibiting osimertinib resistance.…”

Section: Selection and Order Of Use Of Egfr-tkismentioning

confidence: 99%